Targeting protein aggregation for the treatment of degenerative diseases
暂无分享,去创建一个
J. Kelly | Yvonne S. Eisele | E. Powers | C. Fearns | R. L. Wiseman | S. Encalada | C. Monteiro | R. Wiseman | Cecília Monteiro | J. Kelly
[1] R. E. Bendel,et al. Observational report , 2017, Medicine.
[2] E. Siemers,et al. Delayed-start analysis: Mild Alzheimer's disease patients in solanezumab trials, 3.5 years , 2015, Alzheimer's & dementia.
[3] E. Masliah,et al. Novel therapeutic strategy for neurodegeneration by blocking Aβ seeding mediated aggregation in models of Alzheimer's disease , 2015, Neurobiology of Disease.
[4] Lisa M. Ryno,et al. Unfolded protein response‐induced ERdj3 secretion links ER stress to extracellular proteostasis , 2015, The EMBO journal.
[5] B. de Strooper,et al. Learning by failing: ideas and concepts to tackle γ-secretases in Alzheimer's disease and beyond. , 2015, Annual review of pharmacology and toxicology.
[6] M. Benson,et al. Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis , 2014, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[7] Arun K. Ghosh,et al. BACE1 (β-secretase) inhibitors for the treatment of Alzheimer's disease. , 2014, Chemical Society reviews.
[8] P. McLean,et al. α-Synuclein Multimers Cluster Synaptic Vesicles and Attenuate Recycling , 2014, Current Biology.
[9] T. Südhof,et al. α-Synuclein assembles into higher-order multimers upon membrane binding to promote SNARE complex formation , 2014, Proceedings of the National Academy of Sciences.
[10] L. Lannfelt,et al. Immunotherapy targeting α-synuclein protofibrils reduced pathology in (Thy-1)-h[A30P] α-synuclein mice , 2014, Neurobiology of Disease.
[11] Lisa M. Ryno,et al. Unfolded protein response activation reduces secretion and extracellular aggregation of amyloidogenic immunoglobulin light chain , 2014, Proceedings of the National Academy of Sciences.
[12] T. Coelho,et al. CNS involvement in V30M transthyretin amyloidosis: clinical, neuropathological and biochemical findings , 2014, Journal of Neurology, Neurosurgery & Psychiatry.
[13] M. Staufenbiel,et al. Multiple Factors Contribute to the Peripheral Induction of Cerebral β-Amyloidosis , 2014, The Journal of Neuroscience.
[14] S. Prusiner,et al. Distinct synthetic Aβ prion strains producing different amyloid deposits in bigenic mice , 2014, Proceedings of the National Academy of Sciences.
[15] S. Prusiner,et al. Serial propagation of distinct strains of Aβ prions from Alzheimer’s disease patients , 2014, Proceedings of the National Academy of Sciences.
[16] Y. Nishiyama,et al. Metal-dependent amyloid β-degrading catalytic antibody construct. , 2014, Journal of biotechnology.
[17] L. Grinberg,et al. Distinct Tau Prion Strains Propagate in Cells and Mice and Define Different Tauopathies , 2014, Neuron.
[18] D. Otzen,et al. How Epigallocatechin Gallate Can Inhibit α-Synuclein Oligomer Toxicity in Vitro♦ , 2014, The Journal of Biological Chemistry.
[19] L. Iyer,et al. One siRNA pool targeting the λ constant region stops λ light-chain production and causes terminal endoplasmic reticulum stress. , 2014, Blood.
[20] V. Buchman,et al. Multistep process of FUS aggregation in the cell cytoplasm involves RNA-dependent and RNA-independent mechanisms , 2014, Human molecular genetics.
[21] Huanxiang Liu,et al. Exploring the Influence of EGCG on the β-Sheet-Rich Oligomers of Human Islet Amyloid Polypeptide (hIAPP1–37) and Identifying Its Possible Binding Sites from Molecular Dynamics Simulation , 2014, PloS one.
[22] J. Shorter,et al. Reversing deleterious protein aggregation with re-engineered protein disaggregases , 2014, Cell cycle.
[23] Kenji Watanabe,et al. Physiological IgM Class Catalytic Antibodies Selective for Transthyretin Amyloid* , 2014, The Journal of Biological Chemistry.
[24] U. Sengupta,et al. Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles , 2014, The Journal of Neuroscience.
[25] M. Maurer,et al. Quantification of Transthyretin Kinetic Stability in Human Plasma Using Subunit Exchange , 2014, Biochemistry.
[26] R. Vassar,et al. Targeting the β secretase BACE1 for Alzheimer's disease therapy , 2014, The Lancet Neurology.
[27] Zeshan Ahmed,et al. A novel in vivo model of tau propagation with rapid and progressive neurofibrillary tangle pathology: the pattern of spread is determined by connectivity, not proximity , 2014, Acta Neuropathologica.
[28] C. Soto,et al. Aggregate-Depleted Brain Fails to Induce Aβ Deposition in a Mouse Model of Alzheimer's Disease , 2014, PloS one.
[29] D. Seldin,et al. Immunoglobulin light chain amyloidosis , 2014, Expert review of hematology.
[30] S. Radford,et al. Ion Mobility Spectrometry–Mass Spectrometry Defines the Oligomeric Intermediates in Amylin Amyloid Formation and the Mode of Action of Inhibitors , 2013, Journal of the American Chemical Society.
[31] K. Caldwell,et al. Potentiated Hsp104 Variants Antagonize Diverse Proteotoxic Misfolding Events , 2013, Cell.
[32] H. True,et al. Prion-like nuclear aggregation of TDP-43 during heat shock is regulated by HSP40/70 chaperones. , 2014, Human molecular genetics.
[33] E. Nordh,et al. Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. , 2013, JAMA.
[34] M. Goedert,et al. Peripheral administration of tau aggregates triggers intracerebral tauopathy in transgenic mice , 2013, Acta Neuropathologica.
[35] D. Holtzman,et al. Anti-Tau Antibodies that Block Tau Aggregate Seeding In Vitro Markedly Decrease Pathology and Improve Cognition In Vivo , 2013, Neuron.
[36] T. Golde,et al. γ-Secretase inhibitors and modulators. , 2013, Biochimica et biophysica acta.
[37] G. Bitan,et al. Modulators of amyloid protein aggregation and toxicity: EGCG and CLR01 , 2013 .
[38] K. Nilsson,et al. Seeded strain‐like transmission of β‐amyloid morphotypes in APP transgenic mice , 2013, EMBO reports.
[39] B. Meier,et al. Structural and functional characterization of two alpha-synuclein strains , 2013, Nature Communications.
[40] Mathias Jucker,et al. Self-propagation of pathogenic protein aggregates in neurodegenerative diseases , 2013, Nature.
[41] T. Uzu,et al. Altered unfolded protein response is implicated in the age-related exacerbation of proteinuria-induced proximal tubular cell damage. , 2013, The American journal of pathology.
[42] J. Rogers,et al. Allosteric Heat Shock Protein 70 Inhibitors Rapidly Rescue Synaptic Plasticity Deficits by Reducing Aberrant Tau , 2013, Biological Psychiatry.
[43] B. Bettencourt,et al. Safety and efficacy of RNAi therapy for transthyretin amyloidosis. , 2013, The New England journal of medicine.
[44] Huaiyi Yang,et al. De novo generation of infectious prions with bacterially expressed recombinant prion protein , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[45] Teresa Coelho,et al. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy , 2013, Journal of Neurology.
[46] H. Paulson,et al. The E3 ubiquitin ligase CHIP and the molecular chaperone Hsc70 form a dynamic, tethered complex. , 2013, Biochemistry.
[47] M. Farlow,et al. Immunotherapy for Alzheimer's disease. , 2013, Neurologic clinics.
[48] R. Nixon,et al. The role of autophagy in neurodegenerative disease , 2013, Nature Medicine.
[49] F. Brodsky,et al. Heparan sulfate proteoglycans mediate internalization and propagation of specific proteopathic seeds , 2013, Proceedings of the National Academy of Sciences.
[50] Barbara Calamini,et al. Heat Shock Response Activation Exacerbates Inclusion Body Formation in a Cellular Model of Huntington Disease* , 2013, The Journal of Biological Chemistry.
[51] Bin Zhang,et al. Distinct α-Synuclein Strains Differentially Promote Tau Inclusions in Neurons , 2013, Cell.
[52] J. Brodsky,et al. Synthesis and initial evaluation of YM-08, a blood-brain barrier permeable derivative of the heat shock protein 70 (Hsp70) inhibitor MKT-077, which reduces tau levels. , 2013, ACS chemical neuroscience.
[53] B. Nordestgaard,et al. Genetic Stabilization of Transthyretin, Cerebrovascular Disease, and Life Expectancy , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[54] J. Kelly,et al. Toward the molecular mechanism(s) by which EGCG treatment remodels mature amyloid fibrils. , 2013, Journal of the American Chemical Society.
[55] Lisa M. Ryno,et al. Broadly applicable methodology for the rapid and dosable small molecule-mediated regulation of transcription factors in human cells. , 2013, Journal of the American Chemical Society.
[56] B. Ghetti,et al. Brain homogenates from human tauopathies induce tau inclusions in mouse brain , 2013, Proceedings of the National Academy of Sciences.
[57] Yvonne S. Eisele,et al. From Soluble Aβ to Progressive Aβ Aggregation: Could Prion‐Like Templated Misfolding Play a Role? , 2013, Brain pathology.
[58] Lisa M. Ryno,et al. Stress-independent activation of XBP1s and/or ATF6 reveals three functionally diverse ER proteostasis environments. , 2013, Cell reports.
[59] Anjanabha Saha,et al. Inhibition of Usp14 Stimulates the Proteolytic Degradation and Clearance of Misfolded Proteins Associated with Neurodegenerative Diseases , 2013 .
[60] V. Uversky,et al. Imbalance of Hsp70 family variants fosters tau accumulation , 2013, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[61] J. Trojanowski,et al. Evaluation of potential infectivity of Alzheimer and Parkinson disease proteins in recipients of cadaver-derived human growth hormone. , 2013, JAMA neurology.
[62] Virginia M. Y. Lee,et al. Neurofibrillary tangle‐like tau pathology induced by synthetic tau fibrils in primary neurons over‐expressing mutant tau , 2013, FEBS letters.
[63] O. Dewit,et al. Control of AA amyloidosis complicating Crohn's disease: a clinico‐pathological study , 2013, European Journal of Clinical Investigation.
[64] J. Brender,et al. Insights into antiamyloidogenic properties of the green tea extract (−)-epigallocatechin-3-gallate toward metal-associated amyloid-β species , 2013, Proceedings of the National Academy of Sciences.
[65] Carl Frieden,et al. Quantitative analysis of the time course of Aβ oligomerization and subsequent growth steps using tetramethylrhodamine-labeled Aβ , 2013, Proceedings of the National Academy of Sciences.
[66] M. Lubberink,et al. In Vivo Visualization of Amyloid Deposits in the Heart with 11C-PIB and PET , 2013, The Journal of Nuclear Medicine.
[67] D. Housman,et al. Aberrant splicing of HTT generates the pathogenic exon 1 protein in Huntington disease , 2013, Proceedings of the National Academy of Sciences.
[68] J. Trojanowski,et al. Synthetic Tau Fibrils Mediate Transmission of Neurofibrillary Tangles in a Transgenic Mouse Model of Alzheimer's-Like Tauopathy , 2013, The Journal of Neuroscience.
[69] Catherine A. Collins,et al. Activation of Hsp70 reduces neurotoxicity by promoting polyglutamine protein degradation , 2012, Nature chemical biology.
[70] James Rooney,et al. A heavy heart. , 2012, American journal of respiratory and critical care medicine.
[71] R. Kane,et al. Pathogenic Serum Amyloid A 1.1 Shows a Long Oligomer-rich Fibrillation Lag Phase Contrary to the Highly Amyloidogenic Non-pathogenic SAA2.2* , 2012, The Journal of Biological Chemistry.
[72] J. Trojanowski,et al. Pathological α-Synuclein Transmission Initiates Parkinson-like Neurodegeneration in Nontransgenic Mice , 2012, Science.
[73] G. Merlini,et al. Amyloidosis in autoinflammatory syndromes. , 2012, Autoimmunity reviews.
[74] E. Masliah,et al. Antibody-Aided Clearance of Extracellular α-Synuclein Prevents Cell-to-Cell Aggregate Transmission , 2012, The Journal of Neuroscience.
[75] Martin L. Duennwald,et al. Pharmacological tuning of heat shock protein 70 modulates polyglutamine toxicity and aggregation. , 2012, ACS chemical biology.
[76] E. Morignat,et al. Prion-like acceleration of a synucleinopathy in a transgenic mouse model , 2012, Neurobiology of Aging.
[77] Nick C Fox,et al. Clinical and biomarker changes in dominantly inherited Alzheimer's disease. , 2012, The New England journal of medicine.
[78] R. Labaudinière,et al. Tafamidis for transthyretin familial amyloid polyneuropathy , 2012, Neurology.
[79] Steven M. Johnson,et al. The transthyretin amyloidoses: from delineating the molecular mechanism of aggregation linked to pathology to a regulatory-agency-approved drug. , 2012, Journal of molecular biology.
[80] B. Bukau,et al. Chaperone networks in protein disaggregation and prion propagation. , 2012, Journal of structural biology.
[81] W. Klein,et al. Intracellular Aβ-oligomers and early inflammation in a model of Alzheimer's disease , 2012, Neurobiology of Aging.
[82] I. Narita,et al. Treatment with Biologic Agents Improves the Prognosis of Patients with Rheumatoid Arthritis and Amyloidosis , 2012, The Journal of Rheumatology.
[83] S. Prusiner,et al. A Unifying Role for Prions in Neurodegenerative Diseases , 2012, Science.
[84] Stephen J. DeArmond,et al. Purified and synthetic Alzheimer’s amyloid beta (Aβ) prions , 2012, Proceedings of the National Academy of Sciences.
[85] R. Labaudinière,et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade , 2012, Proceedings of the National Academy of Sciences.
[86] E. Wanker,et al. Green tea halts progression of cardiac transthyretin amyloidosis: an observational report , 2012, Clinical Research in Cardiology.
[87] D. Cleveland,et al. Prion-like spread of protein aggregates in neurodegeneration , 2012, The Journal of experimental medicine.
[88] J. Trojanowski,et al. Intracerebral inoculation of pathological α-synuclein initiates a rapidly progressive neurodegenerative α-synucleinopathy in mice , 2012, The Journal of experimental medicine.
[89] K. Dharmarajan,et al. Transthyretin Cardiac Amyloidoses in Older North Americans , 2012, Journal of the American Geriatrics Society.
[90] D. Holtzman,et al. Trans-cellular Propagation of Tau Aggregation by Fibrillar Species* , 2012, The Journal of Biological Chemistry.
[91] Efstathios D. Gennatas,et al. Predicting Regional Neurodegeneration from the Healthy Brain Functional Connectome , 2012, Neuron.
[92] D. Raleigh,et al. Analysis of the inhibition and remodeling of islet amyloid polypeptide amyloid fibers by flavanols. , 2012, Biochemistry.
[93] Mathias Jucker,et al. The Amyloid State of Proteins in Human Diseases , 2012, Cell.
[94] David Eisenberg,et al. Atomic View of a Toxic Amyloid Small Oligomer , 2012, Science.
[95] H. Jono,et al. Long-term survival after liver transplantation in patients with familial amyloid polyneuropathy , 2012, Neurology.
[96] B. de Strooper,et al. Presenilins and γ-secretase: structure, function, and role in Alzheimer Disease. , 2012, Cold Spring Harbor perspectives in medicine.
[97] Monica A. Chalfant,et al. Small Molecule Proteostasis Regulators for Protein Conformational Diseases , 2011, Nature chemical biology.
[98] Bruce L. Miller,et al. Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS , 2011, Neuron.
[99] M. Staufenbiel,et al. Soluble Aβ Seeds Are Potent Inducers of Cerebral β-Amyloid Deposition , 2011, The Journal of Neuroscience.
[100] D. Garza,et al. Firefly luciferase mutants as sensors of proteome stress , 2011, Nature Methods.
[101] R. Falk,et al. Cardiac Amyloidosis: A Treatable Disease, Often Overlooked , 2011, Circulation.
[102] P. Davies,et al. Passive Immunization with Anti-Tau Antibodies in Two Transgenic Models , 2011, The Journal of Biological Chemistry.
[103] M. Kabani,et al. Hsc70 Protein Interaction with Soluble and Fibrillar α-Synuclein* , 2011, The Journal of Biological Chemistry.
[104] D. Selkoe,et al. α-Synuclein occurs physiologically as a helically folded tetramer that resists aggregation , 2011, Nature.
[105] Andreas Bracher,et al. Molecular chaperones in protein folding and proteostasis , 2011, Nature.
[106] J. Kelly,et al. Amyloid-β Forms Fibrils by Nucleated Conformational Conversion of Oligomers , 2011, Nature chemical biology.
[107] B. Ericzon,et al. Long-term data from the Familial Amyloidotic Polyneuropathy World Transplant Registry (FAPWTR) , 2011, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[108] N. Greig,et al. Targets for AD treatment: conflicting messages from γ‐secretase inhibitors , 2011, Journal of neurochemistry.
[109] E. Masliah,et al. Passive Immunization Reduces Behavioral and Neuropathological Deficits in an Alpha-Synuclein Transgenic Model of Lewy Body Disease , 2011, PloS one.
[110] J. Morris,et al. Alzheimer’s Disease: The Challenge of the Second Century , 2011, Science Translational Medicine.
[111] D. Ron,et al. Selective Inhibition of a Regulatory Subunit of Protein Phosphatase 1 Restores Proteostasis , 2011, Science.
[112] D. Seldin,et al. Preclinical Development of siRNA Therapeutics for AL Amyloidosis , 2011, Gene Therapy.
[113] Fred H. Gage,et al. In vivo demonstration that α-synuclein oligomers are toxic , 2011, Proceedings of the National Academy of Sciences.
[114] M. Gertz. Immunoglobulin light chain amyloidosis: 2011 update on diagnosis, risk‐stratification, and management , 2011, American journal of hematology.
[115] Michele Vendruscolo,et al. Amyloid-like Aggregates Sequester Numerous Metastable Proteins with Essential Cellular Functions , 2011, Cell.
[116] P. Aridon,et al. Protective Role of Heat Shock Proteins in Parkinson’s Disease , 2011, Neurodegenerative Diseases.
[117] B. Hyman,et al. Heat‐shock protein 70 modulates toxic extracellular α‐synuclein oligomers and rescues trans‐synaptic toxicity , 2011, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.
[118] Yvonne S. Eisele,et al. The presence of Aβ seeds, and not age per se, is critical to the initiation of Aβ deposition in the brain , 2011, Acta Neuropathologica.
[119] Michael R. Schmidt,et al. Small-molecule conversion of toxic oligomers to nontoxic β-sheet-rich amyloid fibrils. , 2011, Nature chemical biology.
[120] L. Petrucelli,et al. Targeting heat shock proteins in tauopathies. , 2010, Current Alzheimer research.
[121] Frank Baumann,et al. Peripherally Applied Aβ-Containing Inoculates Induce Cerebral β-Amyloidosis , 2010, Science.
[122] Fanling Meng,et al. The flavanol (-)-epigallocatechin 3-gallate inhibits amyloid formation by islet amyloid polypeptide, disaggregates amyloid fibrils, and protects cultured cells against IAPP-induced toxicity. , 2010, Biochemistry.
[123] M. Wolfe. Structure, mechanism and inhibition of γ-secretase and presenilin-like proteases , 2010, Biological chemistry.
[124] Andrey Alexeyenko,et al. Genome-wide pathway analysis implicates intracellular transmembrane protein transport in Alzheimer disease , 2010, Journal of Human Genetics.
[125] Simon Watkins,et al. An Autophagy-Enhancing Drug Promotes Degradation of Mutant α1-Antitrypsin Z and Reduces Hepatic Fibrosis , 2010, Science.
[126] F. Salvi,et al. Transthyretin-related amyloidoses and the heart: a clinical overview , 2010, Nature Reviews Cardiology.
[127] Min Jae Lee,et al. Enhancement of Proteasome Activity by a Small-Molecule Inhibitor of Usp14 , 2010, Nature.
[128] M. Benson,et al. Suppression of choroid plexus transthyretin levels by antisense oligonucleotide treatment , 2010, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[129] C. Mathias,et al. Hereditary fibrinogen A alpha-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. , 2010, Blood.
[130] D. Ehrnhoefer,et al. EGCG remodels mature α-synuclein and amyloid-β fibrils and reduces cellular toxicity , 2010, Proceedings of the National Academy of Sciences.
[131] Matthias Mueller,et al. The HSP70 Molecular Chaperone Is Not Beneficial in a Mouse Model of α-synucleinopathy , 2010, PloS one.
[132] Fei Wang,et al. Generating a Prion with Bacterially Expressed Recombinant Prion Protein , 2010, Science.
[133] M. Dimopoulos,et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[134] R. Falk,et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38α MAPK pathway , 2010, Proceedings of the National Academy of Sciences.
[135] Steven M. Johnson,et al. Structure-based design of kinetic stabilizers that ameliorate the transthyretin amyloidoses. , 2010, Current opinion in structural biology.
[136] B. Strooper,et al. The secretases: enzymes with therapeutic potential in Alzheimer disease , 2010, Nature Reviews Neurology.
[137] C. Jack,et al. Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade , 2010, The Lancet Neurology.
[138] H. Erdem,et al. No regression of renal amyloid mass despite remission of nephrotic syndrome in a patient with TRAPS following etanercept therapy. , 2010, Journal of nephrology.
[139] S. Ikeda,et al. A case with rheumatoid arthritis and systemic reactive AA amyloidosis showing rapid regression of amyloid deposition on gastroduodenal mucosa after a combined therapy of corticosteroid and etanercept , 2011, Rheumatology International.
[140] Lawrence Rajendran,et al. The Transcellular Spread of Cytosolic Amyloids, Prions, and Prionoids , 2009, Neuron.
[141] E. Gavilan,et al. Dysfunction of the unfolded protein response increases neurodegeneration in aged rat hippocampus following proteasome inhibition , 2009, Aging cell.
[142] Elizabeth A Miller,et al. Collapse of proteostasis represents an early molecular event in Caenorhabditis elegans aging , 2009, Proceedings of the National Academy of Sciences.
[143] A. Aguzzi,et al. Induction of cerebral β-amyloidosis: Intracerebral versus systemic Aβ inoculation , 2009, Proceedings of the National Academy of Sciences.
[144] J. Kelly,et al. Secretion of amyloidogenic gelsolin progressively compromises protein homeostasis leading to the intracellular aggregation of proteins , 2009, Proceedings of the National Academy of Sciences.
[145] Martin Beibel,et al. Transmission and spreading of tauopathy in transgenic mouse brain , 2009, Nature Cell Biology.
[146] R. Morimoto,et al. Biological and chemical approaches to diseases of proteostasis deficiency. , 2009, Annual review of biochemistry.
[147] M. Diamond,et al. Propagation of Tau Misfolding from the Outside to the Inside of a Cell* , 2009, Journal of Biological Chemistry.
[148] M. Wolfe. Tau Mutations in Neurodegenerative Diseases* , 2009, Journal of Biological Chemistry.
[149] L. Mucke,et al. Neprilysin Overexpression Inhibits Plaque Formation But Fails to Reduce Pathogenic Aβ Oligomers and Associated Cognitive Deficits in Human Amyloid Precursor Protein Transgenic Mice , 2009, The Journal of Neuroscience.
[150] R. Kopito,et al. Cytoplasmic penetration and persistent infection of mammalian cells by polyglutamine aggregates , 2009, Nature Cell Biology.
[151] S. Wickner,et al. Hsp104 and ClpB: protein disaggregating machines. , 2009, Trends in biochemical sciences.
[152] P. Westermark,et al. Amyloid fibril composition is related to the phenotype of hereditary transthyretin V30M amyloidosis , 2008, The Journal of pathology.
[153] John R. Yates,et al. Chemical and Biological Approaches Synergize to Ameliorate Protein-Folding Diseases , 2008, Cell.
[154] J. Keats,et al. Biologic and genetic characterization of the novel amyloidogenic lambda light chain-secreting human cell lines, ALMC-1 and ALMC-2. , 2008, Blood.
[155] Seth Love,et al. Long-term effects of Aβ42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial , 2008, The Lancet.
[156] J. Kelly,et al. Quantification of the thermodynamically linked quaternary and tertiary structural stabilities of transthyretin and its disease-associated variants: the relationship between stability and amyloidosis. , 2008, Biochemistry.
[157] D. Ehrnhoefer,et al. EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers , 2008, Nature Structural &Molecular Biology.
[158] F. Gejyo,et al. A case of AA amyloidosis associated with rheumatoid arthritis effectively treated with Infliximab , 2008, Rheumatology International.
[159] A. Korczyn. The amyloid cascade hypothesis , 2008, Alzheimer's & Dementia.
[160] Richard I. Morimoto,et al. Adapting Proteostasis for Disease Intervention , 2008, Science.
[161] John Collinge,et al. A General Model of Prion Strains and Their Pathogenicity , 2007, Science.
[162] K. Sarge,et al. Celastrol inhibits polyglutamine aggregation and toxicity though induction of the heat shock response , 2007, Journal of Molecular Medicine.
[163] M. Dimopoulos,et al. Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone , 2007, Haematologica.
[164] G. Merlini,et al. Bortezomib in the treatment of AL amyloidosis: targeted therapy? , 2007, Haematologica.
[165] L. Mucke,et al. Accelerating Amyloid-β Fibrillization Reduces Oligomer Levels and Functional Deficits in Alzheimer Disease Mouse Models* , 2007, Journal of Biological Chemistry.
[166] B. Hazenberg,et al. Beneficial effect of eprodisate (NC-503) on the preservation of kidney function in AA amyloidosis patients : 3-year follow-up results , 2007 .
[167] M. Tsukano,et al. Efficacy of etanercept in patients with AA amyloidosis secondary to rheumatoid arthritis. , 2007, Clinical and experimental rheumatology.
[168] A. Aguzzi,et al. Insights into prion strains and neurotoxicity , 2007, Nature Reviews Molecular Cell Biology.
[169] P. Walter,et al. Signal integration in the endoplasmic reticulum unfolded protein response , 2007, Nature Reviews Molecular Cell Biology.
[170] D. Selkoe,et al. Aβ Oligomers – a decade of discovery , 2007, Journal of neurochemistry.
[171] E. Wanker,et al. Small Molecule Inducers of Heat-Shock Response Reduce polyQ-Mediated Huntingtin Aggregation , 2007, Neurodegenerative Diseases.
[172] C. Rowe,et al. Imaging β-amyloid burden in aging and dementia , 2007, Neurology.
[173] P. Greengard,et al. The Arctic Alzheimer mutation favors intracellular amyloid‐β production by making amyloid precursor protein less available to α‐secretase , 2007, Journal of neurochemistry.
[174] R. Comenzo. Current and emerging views and treatments of systemic immunoglobulin light-chain (Al) amyloidosis. , 2007, Contributions to nephrology.
[175] I. Lott,et al. Alzheimer's disease in Down syndrome: neurobiology and risk. , 2007, Mental retardation and developmental disabilities research reviews.
[176] Yoshiki Sekijima,et al. Diflunisal stabilizes familial amyloid polyneuropathy-associated transthyretin variant tetramers in serum against dissociation required for amyloidogenesis , 2006, Neuroscience Research.
[177] V. Trinkaus-Randall,et al. Role of endocytic inhibitory drugs on internalization of amyloidogenic light chains by cardiac fibroblasts. , 2006, The American journal of pathology.
[178] I. Ferrer,et al. A&bgr; Species Removal After A&bgr;42 Immunization , 2006, Journal of neuropathology and experimental neurology.
[179] Bruce L. Miller,et al. Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis , 2006, Science.
[180] D. Walsh,et al. Exogenous Induction of Cerebral ß-Amyloidogenesis Is Governed by Agent and Host , 2006, Science.
[181] Ehud Cohen,et al. Opposing Activities Protect Against Age-Onset Proteotoxicity , 2006, Science.
[182] P. Merlet,et al. Impact of Liver Transplantation on Cardiac Autonomic Denervation in Familial Amyloid Polyneuropathy , 2006, Medicine.
[183] E. Powers,et al. The kinetics of nucleated polymerizations at high concentrations: amyloid fibril formation near and above the "supercritical concentration". , 2006, Biophysical journal.
[184] L. Raymond,et al. Cleavage at the Caspase-6 Site Is Required for Neuronal Dysfunction and Degeneration Due to Mutant Huntingtin , 2006, Cell.
[185] K. Sleegers,et al. Promoter mutations that increase amyloid precursor-protein expression are associated with Alzheimer disease. , 2006, American journal of human genetics.
[186] G. Merlini,et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. , 2006, Blood.
[187] M. Benson,et al. Targeted suppression of an amyloidogenic transthyretin with antisense oligonucleotides , 2006, Muscle & nerve.
[188] J. Kelly,et al. Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis , 2006, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[189] P. Bross,et al. Reduced heat shock response in human mononuclear cells during aging and its association with polymorphisms in HSP70 genes , 2006, Cell stress & chaperones.
[190] Steven M. Johnson,et al. Native state kinetic stabilization as a strategy to ameliorate protein misfolding diseases: a focus on the transthyretin amyloidoses. , 2005, Accounts of chemical research.
[191] A. Sanabria,et al. Randomized controlled trial. , 2005, World journal of surgery.
[192] R. Falk,et al. Senile systemic amyloidosis presenting with heart failure: a comparison with light chain-associated amyloidosis. , 2005, Archives of internal medicine.
[193] Makoto Hashimoto,et al. Effects of α-Synuclein Immunization in a Mouse Model of Parkinson’s Disease , 2005, Neuron.
[194] J. Kelly,et al. The Biological and Chemical Basis for Tissue-Selective Amyloid Disease , 2005, Cell.
[195] H. Dyson,et al. Intrinsically unstructured proteins and their functions , 2005, Nature Reviews Molecular Cell Biology.
[196] R. Tanzi,et al. Twenty Years of the Alzheimer’s Disease Amyloid Hypothesis: A Genetic Perspective , 2005, Cell.
[197] E. Masliah,et al. Aβ vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease , 2005, Neurology.
[198] R. Kaufman,et al. The mammalian unfolded protein response. , 2003, Annual review of biochemistry.
[199] R. Fletterick,et al. Conversion of a-helices into ,f-sheets features in the formation of the scrapie prion proteins , 2005 .
[200] Mark R. Segal,et al. Inclusion body formation reduces levels of mutant huntingtin and the risk of neuronal death , 2004, Nature.
[201] Philippe Amouyel,et al. α-synuclein locus duplication as a cause of familial Parkinson's disease , 2004, The Lancet.
[202] D. Schenk. Hopes remain for an Alzheimer's vaccine , 2004, Nature.
[203] Joleen T White,et al. Transthyretin aggregation under partially denaturing conditions is a downhill polymerization. , 2004, Biochemistry.
[204] B. Ericzon,et al. Ten years of international experience with liver transplantation for familial amyloidotic polyneuropathy: results from the familial amyloidotic polyneuropathy world transplant registry , 2004, Transplantation.
[205] M. Ohno,et al. BACE1 Deficiency Rescues Memory Deficits and Cholinergic Dysfunction in a Mouse Model of Alzheimer's Disease , 2004, Neuron.
[206] R. Morimoto,et al. Regulation of longevity in Caenorhabditis elegans by heat shock factor and molecular chaperones. , 2003, Molecular biology of the cell.
[207] D. Selkoe,et al. Enhanced Proteolysis of β-Amyloid in APP Transgenic Mice Prevents Plaque Formation, Secondary Pathology, and Premature Death , 2003, Neuron.
[208] C. Dobson. Protein folding and misfolding , 2003, Nature.
[209] P. Lansbury,et al. Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. , 2003, Annual review of neuroscience.
[210] M. Tsukano,et al. Efficacy of cyclophosphamide combined with prednisolone in patients with AA amyloidosis secondary to rheumatoid arthritis , 2003, Clinical Rheumatology.
[211] H. Mori,et al. Human neprilysin is capable of degrading amyloid β peptide not only in the monomeric form but also the pathological oligomeric form , 2003, Neuroscience Letters.
[212] O. Suhr. Impact of liver transplantation on familial amyloidotic polyneuropathy (FAP) patients' symptoms and complications , 2003, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[213] M. Mattson,et al. Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.
[214] M. Pepys,et al. Outcome in systemic AL amyloidosis in relation to changes in concentration of circulating free immunoglobulin light chains following chemotherapy , 2003, British journal of haematology.
[215] J. Sacchettini,et al. Benzoxazoles as transthyretin amyloid fibril inhibitors: synthesis, evaluation, and mechanism of action. , 2003, Angewandte Chemie.
[216] J. Morrison,et al. Tangle and neuron numbers, but not amyloid load, predict cognitive status in Alzheimer’s disease , 2003, Neurology.
[217] C. Holmes,et al. Neuropathology of human Alzheimer disease after immunization with amyloid-β peptide: a case report , 2003, Nature Medicine.
[218] J. Kelly,et al. Prevention of Transthyretin Amyloid Disease by Changing Protein Misfolding Energetics , 2003, Science.
[219] J. Kelly,et al. Sequence-dependent denaturation energetics: A major determinant in amyloid disease diversity , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[220] R. Wetzel,et al. Aggregated polyglutamine peptides delivered to nuclei are toxic to mammalian cells. , 2002, Human Molecular Genetics.
[221] D. Schenk. Amyloid-β immunotherapy for Alzheimer's disease: the end of the beginning , 2002, Nature Reviews Neuroscience.
[222] Christopher A Ross,et al. Polyglutamine Pathogenesis Emergence of Unifying Mechanisms for Huntington's Disease and Related Disorders , 2002, Neuron.
[223] Ronald Wetzel,et al. Huntington's disease age-of-onset linked to polyglutamine aggregation nucleation , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[224] J. Hardy,et al. The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .
[225] P. Lansbury,et al. Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.
[226] Sofia Nyström,et al. Transmissibility of systemic amyloidosis by a prion-like mechanism , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[227] H. Morita,et al. Long-term follow-up of systemic reactive AA amyloidosis secondary to rheumatoid arthritis: successful treatment with intermediate-dose corticosteroid. , 2002, Internal medicine.
[228] B. Olofsson,et al. Progression of cardiomyopathy after liver transplantation in patients with familial amyloidotic polyneuropathy, Portuguese type. , 2002, Transplantation.
[229] E. Check. Nerve inflammation halts trial for Alzheimer's drug , 2002, Nature.
[230] John Q. Trojanowski,et al. Chaperone Suppression of α-Synuclein Toxicity in a Drosophila Model for Parkinson's Disease , 2001, Science.
[231] M. Sousa,et al. Deposition of transthyretin in early stages of familial amyloidotic polyneuropathy: evidence for toxicity of nonfibrillar aggregates. , 2001, The American journal of pathology.
[232] J. Kelly,et al. Trans-Suppression of Misfolding in an Amyloid Disease , 2001, Science.
[233] J. Hamilton,et al. Transthyretin: a review from a structural perspective , 2001, Cellular and Molecular Life Sciences CMLS.
[234] H. M. Petrassi,et al. An engineered transthyretin monomer that is nonamyloidogenic, unless it is partially denatured. , 2001, Biochemistry.
[235] J. Kelly,et al. Transthyretin slowly exchanges subunits under physiological conditions: A convenient chromatographic method to study subunit exchange in oligomeric proteins , 2001, Protein science : a publication of the Protein Society.
[236] L. Lovat,et al. Amyloid load and clinical outcome in AA amyloidosis in relation to circulating concentration of serum amyloid A protein , 2001, The Lancet.
[237] David J. Cummins,et al. Peripheral anti-Aβ antibody alters CNS and plasma Aβ clearance and decreases brain Aβ burden in a mouse model of Alzheimer's disease , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[238] B. Ericzon,et al. Results from the familial amyloidotic polyneuropathy world transplant registry. , 2001, Transplantation proceedings.
[239] H. Lehrach,et al. Geldanamycin activates a heat shock response and inhibits huntingtin aggregation in a cell culture model of Huntington's disease. , 2001, Human molecular genetics.
[240] T. Saido,et al. Metabolic Regulation of Brain Aβ by Neprilysin , 2001, Science.
[241] J. Kelly,et al. Evaluating the binding selectivity of transthyretin amyloid fibril inhibitors in blood plasma , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[242] Brian J. Bacskai,et al. Imaging of amyloid-β deposits in brains of living mice permits direct observation of clearance of plaques with immunotherapy , 2001, Nature Medicine.
[243] J. Hardy,et al. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease , 2000, Nature.
[244] Ralph A. Nixon,et al. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease , 2000, Nature.
[245] A. Olofsson,et al. A comparative analysis of 23 structures of the amyloidogenic protein transthyretin. , 2000, Journal of molecular biology.
[246] S. Lindquist,et al. Nucleated conformational conversion and the replication of conformational information by a prion determinant. , 2000, Science.
[247] R. Motter,et al. Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease , 2000, Nature Medicine.
[248] E. Wanker,et al. Hsp70 and hsp40 chaperones can inhibit self-assembly of polyglutamine proteins into amyloid-like fibrils. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[249] Bernd Bukau,et al. Multistep mechanism of substrate binding determines chaperone activity of Hsp70 , 2000, Nature Structural Biology.
[250] A. Roher,et al. Evidence for Seeding of β-Amyloid by Intracerebral Infusion of Alzheimer Brain Extracts in β-Amyloid Precursor Protein-Transgenic Mice , 2000, The Journal of Neuroscience.
[251] James C. Sacchettini,et al. Rational design of potent human transthyretin amyloid disease inhibitors , 2000, Nature Structural Biology.
[252] M. Saraiva,et al. Vitreous amyloidosis after liver transplantation in patients with familial amyloid polyneuropathy: Ocular synthesis of mutant transthyretin , 2000, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis.
[253] H. Paulson,et al. Suppression of polyglutamine-mediated neurodegeneration in Drosophila by the molecular chaperone HSP70 , 1999, Nature Genetics.
[254] C. Wurth,et al. The most pathogenic transthyretin variant, L55P, forms amyloid fibrils under acidic conditions and protofilaments under physiological conditions. , 1999, Biochemistry.
[255] R. Motter,et al. Immunization with amyloid-β attenuates Alzheimer-disease-like pathology in the PDAPP mouse , 1999, Nature.
[256] William J. Ray,et al. A presenilin-1-dependent γ-secretase-like protease mediates release of Notch intracellular domain , 1999, Nature.
[257] F. Ferrone,et al. Analysis of protein aggregation kinetics. , 1999, Methods in enzymology.
[258] R. Morimoto,et al. Regulation of the Heat Shock Transcriptional Response: Cross Talk between a Family of Heat Shock Factors, Molecular Chaperones, and Negative Regulators the Heat Shock Factor Family: Redundancy and Specialization , 2022 .
[259] Scott A. Peterson,et al. Discovering transthyretin amyloid fibril inhibitors by limited screening. , 1998, Bioorganic & medicinal chemistry.
[260] M. Pepys,et al. Serum amyloid P component scintigraphy in familial amyloid polyneuropathy: regression of visceral amyloid following liver transplantation , 1998, European Journal of Nuclear Medicine.
[261] P. Westermark,et al. Acceleration of amyloid protein A amyloidosis by amyloid-like synthetic fibrils. , 1998, Proceedings of the National Academy of Sciences of the United States of America.
[262] Robert L. Nussbaum,et al. Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease , 1997 .
[263] Christopher M. Dobson,et al. Instability, unfolding and aggregation of human lysozyme variants underlying amyloid fibrillogenesis , 1997, Nature.
[264] P. Lansbury,et al. Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.
[265] Scott A. Peterson,et al. Inhibiting transthyretin amyloid fibril formation via protein stabilization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[266] Allan I. Levey,et al. Familial Alzheimer's Disease–Linked Presenilin 1 Variants Elevate Aβ1–42/1–40 Ratio In Vitro and In Vivo , 1996, Neuron.
[267] J. Kelly,et al. The acid-mediated denaturation pathway of transthyretin yields a conformational intermediate that can self-assemble into amyloid. , 1996, Biochemistry.
[268] H. Budka,et al. Meningocerebrovascular amyloidosis associated with a novel transthyretin mis-sense mutation at codon 18 (TTRD 18G) , 1996, The American journal of pathology.
[269] D. Selkoe,et al. The Swedish mutation causes early-onset Alzheimer's disease by β-secretase cleavage within the secretory pathway , 1995, Nature Medicine.
[270] A Coda,et al. Structure of a complex of two plasma proteins: transthyretin and retinol-binding protein. , 1995, Science.
[271] J R Ghilardi,et al. 1H NMR of A beta amyloid peptide congeners in water solution. Conformational changes correlate with plaque competence. , 1995, Biochemistry.
[272] Leon D. Segal,et al. Functions , 1995 .
[273] D. C. Henckel,et al. Case report. , 1995, Journal.
[274] Maria João,et al. Transthyretin mutations in health and disease , 1995, Human mutation.
[275] L. Amaducci,et al. Aging as a major risk for degenerative diseases of the central nervous system: Editorial commentary , 1994, Current opinion in neurology.
[276] M. Hurle,et al. A role for destabilizing amino acid replacements in light-chain amyloidosis. , 1994, Proceedings of the National Academy of Sciences of the United States of America.
[277] J Carter,et al. Molecular Pathology of Alzheimer's Disease , 2013 .
[278] R. Kisilevsky,et al. During AA amyloidogenesis is proteolytic attack on serum amyloid A a pre- or post- fibrillogenic event? , 1994 .
[279] R J Fletterick,et al. Conversion of alpha-helices into beta-sheets features in the formation of the scrapie prion proteins. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[280] P. Roller,et al. Conformational transitions, dissociation, and unfolding of scrapie amyloid (prion) protein. , 1993, The Journal of biological chemistry.
[281] P. Lansbury,et al. Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.
[282] S. Prusiner,et al. THE SITES OF PrPSc DEPOSITION IN THE BRAIN ARE PRION STRAIN SPECIFIC , 1993 .
[283] B. Wallin,et al. Clinical improvement and amyloid regression after liver transplantation in hereditary transthyretin amyloidosis , 1993, The Lancet.
[284] T. Coelho,et al. A strikingly benign evolution of FAP in an individual found to be a compound heterozygote for two TTR mutations: TTR MET 30 and TTR MET 119 , 1993 .
[285] R. Carp,et al. Brain regional distribution of prion protein PrP27-30 in mice stereotaxically microinjected with different strains of scrapie. , 1993, The Journal of infectious diseases.
[286] J. Kelly,et al. Partial denaturation of transthyretin is sufficient for amyloid fibril formation in vitro. , 1992, Biochemistry.
[287] C. Glabe,et al. Intracellular accumulation and resistance to degradation of the Alzheimer amyloid A4/beta protein. , 1992, Proceedings of the National Academy of Sciences of the United States of America.
[288] G. Drewes,et al. Mitogen activated protein (MAP) kinase transforms tau protein into an Alzheimer‐like state. , 1992, The EMBO journal.
[289] J. Hardy,et al. Alzheimer's disease: the amyloid cascade hypothesis. , 1992, Science.
[290] R. Marsh,et al. Biochemical and physical properties of the prion protein from two strains of the transmissible mink encephalopathy agent , 1992, Journal of virology.
[291] D. Salmon,et al. Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.
[292] G. Holmgren,et al. Biochemical effect of liver transplantation in two Swedish patients with familial amyloidotic polyneuropathy (FAP‐met30) , 1991, Clinical genetics.
[293] K. Fischbeck,et al. Androgen receptor gene mutations in X-linked spinal and bulbar muscular atrophy , 1991, Nature.
[294] M. Pericak-Vance,et al. Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease , 1991, Nature.
[295] J. Hardy,et al. Amyloid deposition as the central event in the aetiology of Alzheimer's disease. , 1991, Trends in pharmacological sciences.
[296] K. Shimada,et al. [Familial amyloidotic polyneuropathy]. , 1990, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.
[297] K. Sletten,et al. Fibril in senile systemic amyloidosis is derived from normal transthyretin. , 1990, Proceedings of the National Academy of Sciences of the United States of America.
[298] G. Glenner,et al. Alzheimerʼs disease and Downʼs syndrome: sharing of a unique cerebrovascular amyloid fibril protein , 1988 .
[299] D. Selkoe,et al. Microtubule-associated protein tau (? ) is a major antigenic component of paired helical filaments in Alzheimer disease , 1987 .
[300] D. Selkoe,et al. Microtubule-associated protein tau (tau) is a major antigenic component of paired helical filaments in Alzheimer disease. , 1986, Proceedings of the National Academy of Sciences of the United States of America.
[301] J. Hofrichter,et al. Kinetics of sickle hemoglobin polymerization. II. A double nucleation mechanism. , 1985, Journal of molecular biology.
[302] E. Craig,et al. The Heat Shock Respons , 1985 .
[303] E. Craig,et al. The heat shock response. , 1985, CRC critical reviews in biochemistry.
[304] S J Oatley,et al. Structure of prealbumin: secondary, tertiary and quaternary interactions determined by Fourier refinement at 1.8 A. , 1977, Journal of molecular biology.
[305] A. Baer. The genetic perspective , 1977 .
[306] J. Hofrichter,et al. Kinetics and mechanism of deoxyhemoglobin S gelation: a new approach to understanding sickle cell disease. , 1974, Proceedings of the National Academy of Sciences of the United States of America.
[307] G. Glenner,et al. Amyloid Fibril Proteins: Proof of Homology with Immunoglobulin Light Chains by Sequence Analyses , 1971, Science.
[308] M. Skinner,et al. Characterization of the Amyloid Fibril as a Cross-β Protein∗ , 1969, Proceedings of the Society for Experimental Biology and Medicine. Society for Experimental Biology and Medicine.
[309] C ANDRADE,et al. A peculiar form of peripheral neuropathy; familiar atypical generalized amyloidosis with special involvement of the peripheral nerves. , 1952, Brain : a journal of neurology.